Phase III study with Finerenone in Type II Diabetes and DKD, CV

• Research type

  Research Study

• Full title

  A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.

• IRAS ID

  183584

• Contact name

  Kieran McCafferty

• Contact email

  kieran.mccafferty4@nhs.net

• Sponsor organisation

  Bayer plc

• Eudract number

  2015-000950-39

• Duration of Study in the UK

  3 years, 4 months, 21 days

• Research summary

  Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and diabetic kidney disease

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  15/SC/0448

• Date of REC Opinion

  26 Aug 2015

• REC opinion

  Favourable Opinion